JP2015508099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508099A5 JP2015508099A5 JP2014558733A JP2014558733A JP2015508099A5 JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5 JP 2014558733 A JP2014558733 A JP 2014558733A JP 2014558733 A JP2014558733 A JP 2014558733A JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- conr
- conditions
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601101P | 2012-02-21 | 2012-02-21 | |
| US61/601,101 | 2012-02-21 | ||
| PCT/US2012/070252 WO2013126132A1 (en) | 2012-02-21 | 2012-12-18 | Cyclic diaminopyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508099A JP2015508099A (ja) | 2015-03-16 |
| JP2015508099A5 true JP2015508099A5 (enExample) | 2016-12-08 |
| JP6059260B2 JP6059260B2 (ja) | 2017-01-11 |
Family
ID=47459190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558733A Expired - Fee Related JP6059260B2 (ja) | 2012-02-21 | 2012-12-18 | 環状ジアミノピリジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9073944B2 (enExample) |
| EP (1) | EP2817306B1 (enExample) |
| JP (1) | JP6059260B2 (enExample) |
| CN (1) | CN104254531B (enExample) |
| AR (1) | AR090103A1 (enExample) |
| AU (1) | AU2012370450B2 (enExample) |
| CA (1) | CA2865040C (enExample) |
| ES (1) | ES2552518T3 (enExample) |
| IL (1) | IL233986A (enExample) |
| WO (1) | WO2013126132A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40344A (fr) | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| EP3842442B1 (en) | 2016-12-22 | 2023-11-01 | Precision Pharmaceuticals, Inc. | Compositions and methods for inhibiting arginase activity |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115515588A (zh) | 2020-02-14 | 2022-12-23 | 萨克生物研究学院 | 大环ulk1/2抑制剂 |
| CN116528877A (zh) * | 2020-10-05 | 2023-08-01 | 默克专利股份公司 | 用于治疗血液障碍和实体瘤的lmp7选择性抑制剂 |
| JP7556310B2 (ja) * | 2021-02-26 | 2024-09-26 | スズキ株式会社 | 電動車両 |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| AU2023233811A1 (en) * | 2022-03-14 | 2024-09-19 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics and uses thereof |
| WO2024017251A1 (zh) * | 2022-07-18 | 2024-01-25 | 江苏恒瑞医药股份有限公司 | 抑制并诱导egfr降解的大环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| CN1863780A (zh) * | 2002-08-14 | 2006-11-15 | 沃泰克斯药物股份有限公司 | 蛋白激酶抑制剂及其应用 |
| WO2005011597A2 (en) * | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN102358738A (zh) * | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| JP2009518443A (ja) * | 2005-12-06 | 2009-05-07 | リゲル ファーマシューティカルズ インコーポレーティッド | 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤 |
| JP4653842B2 (ja) * | 2006-02-17 | 2011-03-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物 |
| ES2380551T3 (es) * | 2006-11-21 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos |
| CA2735420C (en) | 2008-09-08 | 2016-06-28 | Merck Patent Gmbh | Macrocyclic pyrimidines as protein kinase inhibitors |
-
2012
- 2012-12-18 JP JP2014558733A patent/JP6059260B2/ja not_active Expired - Fee Related
- 2012-12-18 CA CA2865040A patent/CA2865040C/en active Active
- 2012-12-18 WO PCT/US2012/070252 patent/WO2013126132A1/en not_active Ceased
- 2012-12-18 CN CN201280070330.7A patent/CN104254531B/zh not_active Expired - Fee Related
- 2012-12-18 EP EP12808646.9A patent/EP2817306B1/en active Active
- 2012-12-18 ES ES12808646.9T patent/ES2552518T3/es active Active
- 2012-12-18 US US14/379,625 patent/US9073944B2/en active Active
- 2012-12-18 AU AU2012370450A patent/AU2012370450B2/en not_active Ceased
-
2013
- 2013-02-21 AR ARP130100516 patent/AR090103A1/es unknown
-
2014
- 2014-08-06 IL IL233986A patent/IL233986A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529657A5 (enExample) | ||
| JP2015509512A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| JP2015508086A5 (enExample) | ||
| JP2014513729A5 (enExample) | ||
| US20150232434A1 (en) | Stat3 inhibitors and their anticancer use | |
| JP2012507522A5 (enExample) | ||
| JP2015508085A5 (enExample) | ||
| JP2014510774A5 (enExample) | ||
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| RU2013148146A (ru) | Производные адамантила | |
| CN111727042A (zh) | 微管蛋白抑制剂 | |
| JP2020002165A (ja) | ジピコリルアミン誘導体及びそれらの薬学的使用 | |
| US20250281515A1 (en) | Carborane compounds, carborane analogs, and methods of use thereof | |
| AU2016324495A1 (en) | Carborane compounds and methods of use thereof | |
| US9340501B2 (en) | Marinopyrrole derivatives as anticancer agents | |
| US20160362386A1 (en) | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | |
| WO2023086365A1 (en) | Compositions comprising amino lipid compounds and methods of making and use thereof | |
| WO2023141538A1 (en) | Compositions comprising lipid compounds and methods of making and use thereof | |
| US8871983B2 (en) | Lipid compounds for suppression of tumorigenesis | |
| WO2019102054A1 (es) | Análogos no glicosídicos de alfa-galactosilceramida como activadores de células nkt | |
| US20160214941A1 (en) | Compounds for lnhibition of Unregulated Cell Growth | |
| US20250289837A1 (en) | Mitochondriotropic heteroaryl benzamide potassium channel kv1.3 inhibitors | |
| CA2914439A1 (en) | Pharmaceutical compositions | |
| US20250188098A1 (en) | Carborane compounds and methods of use thereof |